OncoGenex Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing new therapies to address treatment resistance in cancer patients. Each product candidate in the company’s diverse oncology pipeline has a distinct mechanism of action and represents a unique opportunity for cancer drug development. OncoGenex has entered into a worldwide collaboration and license agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize custirsen, OncoGenex’s lead drug candidate. For more information, visit the company’s Web site at www.oncogenex.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: